Chemical postevolution: Difference between revisions
wikademia>Paxillus No edit summary |
wikademia>Wikademia No edit summary |
||
| (13 intermediate revisions by 11 users not shown) | |||
| Line 1: | Line 1: | ||
'''Chemical postevolution''' is the structural optimization of (already evolutionary optimized) [[natural product]]s by synthetic chemical means. It is additional and often structurally orthogonal to | '''Chemical postevolution''' is the structural optimization of (already evolutionary optimized) [[natural product]]s by synthetic chemical means such as de novo synthesis and semisynthesis. It is additional and often structurally orthogonal to evolution by [[natural selection]].<ref> F. von Nussbaum, M. Brands, B. Hinzen, S. Weigand, D. Häbich, ''Angew. Chem.'' '''2006''', ''118'', 5194–5254; ''Angew. Chem. Int. Ed.'' '''2006''', ''45'', 5072–5129. Antibacterial Natural Products in Medicinal Chemistry—Exodus or Revival? PMID 16881035</ref> Whereas the term "[[Chemical Evolution]]" refers to an iterative optimization of any possible chemical structure,{{Fact|date=February 2009}} the term Chemical Postevolution especially refers to the biological improvement of antibiotic natural products by synthetic organic chemistry, primarily in antiinfective and anticancer research. | ||
{{?}} | |||
== Application in drug discovery == | ==Application in drug discovery== | ||
Natural products have provided the majority of [[lead structure]]s for marketed [[antibiotics]].<ref> C. Walsh, Antibiotics, actions, origins, resistance, 1. Aufl., ASM, | Natural products have provided the majority of [[lead structure]]s for marketed [[antibiotics]].<ref> C. Walsh, Antibiotics, actions, origins, resistance, 1. Aufl., ASM, | ||
Washington, DC, 2003</ref> But, only a few “pure” natural products fulfill the complex profile required for a pharmaceutical drug. A drug has to match additional physicochemical, pharmacological, toxicological and technical requirements that have not been selectors in the evolution of antibacterial [[secondary metabolites]]. On the other hand, natural products offer excellent starting points for medicinal chemistry. To create a drug, nature’s blueprints often have to be improved by [[semisynthesis]] or [[de novo synthesis]] to repair typical deficiencies such as limited stability, low solubility, narrow [[antibacterial spectrum]], poor in vivo efficacy, etc. Chemical structure defines biological activity. Complementary to nature, a chemist can explore white spots in structural space and biological activity that have never been explored by any organism over the entire period of evolution. | Washington, DC, 2003</ref> But, only a few “pure” natural products fulfill the complex profile required for a pharmaceutical drug. A drug has to match additional physicochemical, pharmacological, toxicological and technical requirements that have not been selectors in the evolution of antibacterial [[secondary metabolites]]. On the other hand, natural products offer excellent starting points for medicinal chemistry. To create a drug, nature’s blueprints often have to be improved by [[semisynthesis]] or [[de novo synthesis]] to repair typical deficiencies such as limited stability, low solubility, narrow [[antibacterial spectrum]], poor in vivo efficacy, etc. Chemical structure defines biological activity. Complementary to nature, a chemist can explore white spots in structural space and biological activity that have never been explored by any organism over the entire period of evolution. | ||
== Examples == | ==Examples== | ||
Various natural antibiotics have already been optimized. Classical examples are the beta-lactam antibiotics (e.g. [[penicillin G]] to [[meticillin]]), the glycopeptides ([[chloroeremomycin]] to [[oritavancin]]) or the macrolides ([[erythromycin]] A to [[telithromycin]]). Since 2006 [[platensimycin]].<ref name=Wang2006>Jun Wang ''et al'', ''Platensimycin is a selective FabF inhibitor with potent antibiotic properties'', Nature 441, 358-361 (18 May 2006) PMID 16710421</ref> has been the target for various synthetic studies aiming at a chemical postevolution of this potent FabF inhibitor. Various other classes of natural antibiotics are now in the focus of chemical postevolution.<ref> K. C. Nicolaou, Jason S. Chen, David J. Edmonds, Anthony A. Estrada, ''Angew. Chem.'' '''2009''', ''121'', 670–732; ''Angew. Chem. Int. Ed.'' '''2009''', ''48'', 660-719. Recent Advances in the Chemistry and Biology of Naturally Occurring Antibiotics | Various natural antibiotics have already been optimized. Classical examples are the beta-lactam antibiotics (e.g. [[penicillin G]] to [[meticillin]]), the glycopeptides ([[chloroeremomycin]] to [[oritavancin]]) or the macrolides ([[erythromycin]] A to [[telithromycin]]). Since 2006 [[platensimycin]].<ref name=Wang2006>Jun Wang ''et al.'', ''Platensimycin is a selective FabF inhibitor with potent antibiotic properties'', Nature 441, 358-361 (18 May 2006) PMID 16710421</ref> has been the target for various synthetic studies aiming at a chemical postevolution of this potent FabF inhibitor. Various other classes of natural antibiotics are now in the focus of chemical postevolution.<ref> K. C. Nicolaou, Jason S. Chen, David J. Edmonds, Anthony A. Estrada, ''Angew. Chem.'' '''2009''', ''121'', 670–732; ''Angew. Chem. Int. Ed.'' '''2009''', ''48'', 660-719. Recent Advances in the Chemistry and Biology of Naturally Occurring Antibiotics | ||
PMID 19130444</ref> | PMID 19130444</ref> | ||
== References == | ==References== | ||
<references/> | <references/> | ||
[[Category: | [[Category:Chemistry]] | ||